New imaging study tracks cancer drug's journey in patients
NCT ID NCT05963867
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 35 times
Summary
This study looks at how the medicine BI 764532 moves through the body and reaches tumors in people with advanced small cell lung cancer or other neuroendocrine cancers. About 12 adults who have not responded to other treatments will receive the drug and undergo PET scans to track it. The goal is to understand where the drug goes, not to cure the disease, and results may guide future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC Locatie VUMC
RECRUITINGAmsterdam, 1081HV, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.